Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity (2010 - 2026)

Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $257.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 33.72% year-over-year to $257.9 million; the TTM figure through Mar 2026 stood at $974.9 million (up 87.1% YoY), while the FY2025 annual figure was $277.2 million, up 70.16% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $257.9 million, down from $277.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $277.2 million in Q4 2025, with the low at $70.3 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $187.4 million (2025), against an average of $190.1 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 55.99% in 2024, then jumped 166.49% in 2025.
• Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity stood at $225.7 million in 2022, then plunged by 31.56% to $154.5 million in 2023, then gained by 5.46% to $162.9 million in 2024, then soared by 70.16% to $277.2 million in 2025, then retreated by 6.95% to $257.9 million in 2026.
• Business Quant data shows TNXP's Liabilities and Shareholders Equity at $257.9 million in Q1 2026, $277.2 million in Q4 2025, and $252.4 million in Q3 2025.